| Business Summary | | Hollis-Eden
Pharmaceuticals
Inc.,
a
development-stage
pharmaceutical
company,
is
engaged
in
the
discovery,
development
and
commercialization
of
products
for
the
treatment
of
infectious
diseases
and
immune
system
disorders,
including
HIV/AIDS,
hepatitis
B
and
C
and
malaria.
The
Company
is
focusing
its
initial
development
efforts
on
a
potent
series
of
immune
regulating
hormones
and
hormone
analogs.
The
Company's
lead
compound
in
this
series,
HE2000,
is
currently
in
Phase
II
clinical
studies
in
HIV.
In
addition,
through
its
relationship
with
Aeson
Theraputics,
Inc.,
the
Company
has
a
right
to
acquire
significant
additional
intellectual
property
in
this
field,
including
the
rights
to
a
compound
in
this
class
that
is
in
Phase
II
clinical
trials
for
the
treatment
of
cardiovascular
disease
and
actinic
keratosis,
a
precursor
to
squamous
cell
cancer. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | HEPH
is
a
development-stage
pharmaceutical
company
engaged
in
the
discovery,
development,
and
commercialization
of
products
for
the
treatment
of
a
number
of
diseases
including
HIV/AIDS,
hepatitis
and
malaria.
For
the
six
months
ended
6/30/01,
the
Company
reports
no
revenues.
Net
loss
decreased
26%
to
$7.4
million.
Results
reflect
decreased
research
and
development
costs
related
to
common
stock,
option,
and
warrants
grants
for
collaborations. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Richard Hollis, 48 Chairman,
Pres, CEO | $768K | Daniel Burgess, 39 COO
and Chief Financial Officer | 288K | Thomas Charles Merigan, Jr., M.D., 67 Scientific
Advisor | -- | James Frincke, Ph.D., 50 Exec.
VP of R&D | 240K | Robert Weber, 50 VP,
Controller, CAO | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|